

A/seq

**NEW UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)***(Only for new nonprovisional applications under 37 CFR 1.53(b))*Docket No.  
2813-LTotal Pages in this Submission  
3**TO THE ASSISTANT COMMISSIONER FOR PATENTS**Box Patent Application  
Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

**MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING HEMATOPOIETIC CELLS**

and invented by:

**Stewart D. Lyman and M. Patricia Beckmann**If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:☒ **Continuation**   ☐ **Divisional**   ☐ **Continuation-in-part (CIP)**   of prior application No.: 08/444,627


Enclosed are:

**Application Elements**

1. ☒ Filing fee as calculated and transmitted as described below
2. ☒ Specification having 50 56 pages and including the following:

- a. ☒ Descriptive Title of the Invention
  - b. ☒ Cross References to Related Applications *(if applicable)*
  - c. ☐ Statement Regarding Federally-sponsored Research/Development *(if applicable)*
  - d. ☐ Reference to Microfiche Appendix *(if applicable)*
  - e. ☒ Background of the Invention
  - f. ☒ Brief Summary of the Invention
  - g. ☐ Brief Description of the Drawings *(if drawings filed)*
  - h. ☒ Detailed Description
  - i. ☒ Claim(s) as Classified Below
  - j. ☒ Abstract of the Disclosure
3. ☐ Drawing(s) *(when necessary as prescribed by 35 USC 113)*
  - a. ☐ Formal
  - b. ☐ Informal

Number of Sheets \_\_\_\_\_

  
Reg. 32.655

12/19/97

06544 U.S. PTO

08994463.121997

**NEW UTILITY PATENT APPLICATION TRANSMITTAL**  
**(Large Entity)**

*(Only for new nonprovisional applications under 37 CFR 1.53(b))*

Docket No.  
2813-L

Total Pages in this Submission  
3

**Application Elements (Continued)**

4. ☒ Oath or Declaration
- a. ☐ Newly executed (*original or copy*) ☐ Unexecuted
- b. ☒ Copy from a prior application (37 CFR 1.63(d)) (*for continuation/divisional application only*)
- c. ☒ With Power of Attorney ☐ Without Power of Attorney
5. ☒ Incorporation By Reference (*usable if Box 4b is checked*)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.
6. ☐ Computer Program in Microfiche (*Appendix*)
7. ☒ Nucleotide and/or Amino Acid Sequence Submission (*if applicable, all must be included*)
- a. ☐ Paper Copy
- b. ☐ Computer Readable Copy (*identical to computer copy*)
- c. ☒ Statement Verifying Identical Paper and Computer Readable Copy

**Accompanying Application Parts**

8. ☐ Assignment Papers (*cover sheet & document(s)*)
9. ☐ 37 CFR 3.73(B) Statement (*when there is an assignee*)
10. ☐ English Translation Document (*if applicable*)
11. ☒ Information Disclosure Statement/PTO-1449 ☒ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Acknowledgment postcard
14. ☒ Certificate of Mailing
- ☐ First Class ☒ Express Mail (*Specify Label No.:* EM551617612US)
15. ☐ Certified Copy of Priority Document(s) (*if foreign priority is claimed*)

# NEW UTILITY PATENT APPLICATION TRANSMITTAL (Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.  
2813-L

Total Pages in this Submission  
3

## Accompanying Application Parts (Continued)

16. ☐ Additional Enclosures (please identify below):


## Fee Calculation and Transmittal

### CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	8	- 20 =	0	x \$22.00	\$0.00
Indep. Claims	8	- 3 =	5	x \$82.00	\$410.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
BASIC FEE					\$790.00
OTHER FEE (specify purpose) _____					\$0.00
TOTAL FILING FEE					\$1,200.00

- ☐ A check in the amount of \_\_\_\_\_ to cover the filing fee is enclosed.
- ☒ The Commissioner is hereby authorized to charge and credit Deposit Account No. 09-0089 as described below. A duplicate copy of this sheet is enclosed.
- ☒ Charge the amount of \$1,200.00 as filing fee.
- ☒ Credit any overpayment.
- ☒ Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
- ☐ Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).

Dated: December 19, 1997

  
Signature

Stephen L. Malaska,  
Registration No. 32,655

IMMUNEX CORPORATION  
Law Department  
51 University Street  
Seattle, Washington 98101  
Telephone: (206) 587-0430 Fax: (206) 233-0644

CC:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Attorney Docket No.: 2813-L

Stewart D. Lyman and M. Patricia Beckmann

Group Art No. Unknown

Serial No.: -to be assigned-

Examiner: Unknown

Filed: December 19, 1997

For: MEDIUM CONTAINING FLT3 LIGAND FOR CULTURING  
HEMATOPOIETIC CELLS

CERTIFICATE OF MAILING BY EXPRESS MAIL

BOX SEQUENCE

Hon. Commissioner of Patents  
and Trademarks  
Washington, D.C. 20231

EXPRESS MAIL LABEL NUMBER: EM551617612US

I hereby certify that the enclosed correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR §1.10 on the date listed below, and is addressed to BOX SEQUENCE, Hon. Commissioner of Patents and Trademarks, Washington, D.C. 20231.

Postcard

Transmittal Letter (+ 1 of Fee page) 56

Specification, abstract and claims (60 pages)

Preliminary Amendment

Copy of Declaration and Power of Attorney

Form PTO 1449

Cited references (5)

Information Disclosure Statement

Statement Under 37 C.F.R. 1.821(e) (1 page)

Date:

12/19/97

Signed:

Camilla C. Edwards  
Camilla C. Edwards

0394458 121997